T. Rowe Price Associates
ROIV icon

T. Rowe Price Associates’s Roivant Sciences ROIV Stock Holding History

T. Rowe Price Associates’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$170M Sell
4,816,741
-2,175,395
-31% -$64.3M 0.02% 551
2026
Q1 		$194M Buy
6,992,136
+1,657,011
+31% +$42.6M 0.02% 469
2025
Q4 		$116M Buy
5,335,125
+2,414,629
+83% +$47.6M 0.01% 601
2025
Q3 		$44.2M Buy
2,920,496
+1,449,273
+99% +$17.9M ﹤0.01% 838
2025
Q2 		$16.6M Buy
1,471,223
+1,210,181
+464% +$13.1M ﹤0.01% 998
2025
Q1 		$2.63M Buy
261,042
+12,778
+5% +$138K ﹤0.01% 1491
2024
Q4 		$2.94M Sell
248,264
-25,367
-9% -$300K ﹤0.01% 1468
2024
Q3 		$3.16M Buy
273,631
+26,407
+11% +$301K ﹤0.01% 1437
2024
Q2 		$2.61M Sell
247,224
-353,645
-59% -$3.88M ﹤0.01% 1444
2024
Q1 		$6.33M Sell
600,869
-3,185,744
-84% -$34.4M ﹤0.01% 1175
2023
Q4 		$42.5M Buy
3,786,613
+74,131
+2% +$722K 0.01% 753
2023
Q3 		$43.4M Buy
3,712,482
+3,662,354
+7,306% +$41.4M 0.01% 731
2023
Q2 		$506K Buy
+50,128
New +$448K ﹤0.01% 2124

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

T. Rowe Price Associates's ROIV Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Roivant Sciences (ROIV) stake by 31% in Q2 2026, selling an estimated $64.3M and leaving 4,816,741 shares worth $170M. The position accounts for 0.02% of the portfolio, ranked #551.

T. Rowe Price Associates first reported a position in ROIV in Q2 2023 and has held it in 13 quarters since. The position peaked at $194M in Q1 2026. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • T. Rowe Price Associates held 4,816,741 shares of Roivant Sciences worth $170M as of Q2 2026.
  • T. Rowe Price Associates sold 2,175,395 Roivant Sciences shares in Q2 2026, an estimated $64.3M.
  • Roivant Sciences made up 0.02% of T. Rowe Price Associates's portfolio in Q2 2026, its #551 holding.
  • T. Rowe Price Associates first reported a position in Roivant Sciences in Q2 2023 and has held it in 13 quarters since.
  • T. Rowe Price Associates's Roivant Sciences position peaked at $194M in Q1 2026.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.